Abstract: A pumping device includes a seal cap unit including a cap, an air relief member connected with the cap, and a regulating member connected with the air relief member. The cap has an air inlet hole and an air outlet hole. The air outlet hole has a through hole. The air relief member is mounted on the air outlet hole and has a guide hole and a plurality of apertures. The regulating member has an air relief hole and a plurality of draining holes. Thus, the air relief hole of the regulating member and the pressure relief member provide a double pressure relief function to release the excessive air pressure in the barrel.

Abstract: The invention relates to a method for discovering specific functional antibodies, in particular to a method for discovering specific functional antibodies based on sequence composition and frequency analysis of variable regions of immune host antibodies. Compared with conventional high-throughput antibody sequencing method, this method can quickly and accurately obtain the full-length sequence of the variable region of antibody containing candidate CDR3, the success rate of antibody gene pairing is high and it is suitable for the detection of few samples, and improves the efficiency of obtaining specific functional antibodies.

Abstract: The present invention identifies biomarkers that are diagnostic of nerve cell injury and/or neuronal disorders. Detection of different biomarkers of the invention are also diagnostic of the degree of severity of nerve injury, the cell(s) involved in the injury, and the subcellular localization of the injury.

Abstract: A process and assay for determining the neurological condition in a subject is provided whereby the level of one or more neuroactive biomarkers is measured in a sample obtained from the subject. The processes and assay include measurement of multiple neuroactive biomarkers for synergistic determination of a neurological condition such as neurological damage due to injury, disease, contact with a compound, or other source.

Abstract: Processes and materials are provided for the detection, diagnosis, or determination of the severity of a neurological injury or condition, including traumatic brain injury, multiple-organ injury, stroke, Alzeimer's disease, Parkinson disease and Chronic Traumatic Encephalopathy (CTE). The processes and materials include biomarkers detected or measured in a biological sample such as whole blood, serum, plasma, or CSF. Such biomarkers include Tau and GFAP proteins, their proteolytic breakdown products, brain specific or enriched micro-RNA, and brain specific or enriched protein directed autoantibodies. The processes and materials are operable to detect the presence of absence of acute, subacute or chronic brain injuries and predict outcome for the brain injury.

Abstract: The present invention provides a method for constructing a next-generation sequencing library for detecting low-frequency mutations, and a kit thereof. The constructing method comprises steps of obtaining blunt-end DNA fragments, obtaining DNA fragments with A-tail at the 3? end, obtaining adapter-added DNA fragments using a specific nucleotide sequence and obtaining amplification products using a specific nucleotide sequence.

Abstract: Provided herein are methods of cloning into vectors.

Abstract: The following invention is used to recycle broken pieces of crayons, A crayon package comprises a portion of the box which can be placed in an oven, said portion of the box being detachable from the package, said portion of the box is designed as a crayon recycling cartridge, the crayon recycling cartridge comprises slots, the edges of the slots are provided with guide slopes, the bottom of the guide slope is connected to the edge of the slot and the slot is expanded outward, which increases the volume of the slot. The used crayons will be placed into the slots, melted and re-casted into new crayons. And if too much used crayons are placed above the edge of the slots, when the crayon melts, the guide slope will catch the melted crayons, sending it back down into the slots, fitting to the volume of the slots.

Abstract: Processes and materials are provided for the detection, diagnosis, or determination of the severity of a neurological injury or condition, including traumatic brain injury, multiple-organ injury, stroke, Alzeimer's disease, Parkinson disease and Chronic Traumatic Encephalopathy (CTE). The processes and materials include biomarkers detected or measured in a biological sample such as whole blood, serum, plasma, or CSF. Such biomarkers include Tau and GFAP proteins, their proteolytic breakdown products, brain specific or enriched micro-RNA, and brain specific or enriched protein directed autoantibodies. The processes and materials are operable to detect the presence of absence of acute, subacute or chronic brain injuries and predict outcome for the brain injury.

Abstract: Described herein are multiplexed RNA, including miRNA, PCR-based assays.

Abstract: The invention concerns a non-human animal model useful for sensitively studying gene-gene interactions over a wide genetic background; methods for producing the animal model; and methods for studying gene-gene interactions using an animal model of the invention.

Abstract: An oceaneering test platform device for simulating oceaneering working conditions is disclosed. The oceaneering test platform device comprises a main body, a lifting unit, a plurality of spud legs connected to the main body by the lifting unit, a plurality of base units located correspondingly to the plurality of spud legs and one or more vertical driving unit to enable vertical movement of at least one of the plurality of spud legs. The test platform device facilitates simulation of possible effects caused by unstable and complex ocean environments to an offshore work platform.

Abstract: The present invention identifies biomarkers that are diagnostic of nerve cell injury and/or neuronal disorders. Detection of different biomarkers of the invention are also diagnostic of the degree of severity of nerve injury, the cell(s) involved in the injury, and the subcellular localization of the injury.

Abstract: The subject invention provides a robust, quantitative, and reproducible process and assay for diagnosis of a neurological condition in a subject. The invention provides measurement of two or more biomarkers in a biological fluid such as CSF or serum resulting in a synergistic mechanism for determining the extent of neurological damage in a subject with an abnormal neurological condition and for discerning subtypes thereof or tissue types subjected to damage.

Abstract: Anti-cytokine therapy has revolutionized immunological disease treatment, but is not always effective and subject to treatment resistance as the cytokine cascade is highly redundant and multiple cytokines are involved in inflammation. Targeting a critical common regulator of inflammatory effectors is desirable. Lipopolysaccharide (LPS)-responsive beige-like anchor (LRBA) is a master regulator of multiple genes important for inflammation. Subcellular localization shows that LRBA translocated to the nucleus upon LPS stimulation and colocalized with multiple proteins associated with the endosome membrane system, indicating a critical role in membrane/vesicle trafficking essential for deposition, secretion and signal transduction of immune effectors.

Abstract: Provided herein are methods of cloning into vectors.

Abstract: The present invention identifies biomarkers that are diagnostic of nerve cell injury and/or neuronal disorders. Detection of different biomarkers of the invention are also diagnostic of the degree of severity of nerve injury, the cell(s) involved in the injury, and the subcellular localization of the injury.

Abstract: A robust, quantitative, and reproducible process and assay for diagnosis of a neurological condition in a subject is provided. With measurement of one or more autoantibodies to biomarkers in a biological fluid such as CSF or serum, the extent of neurological damage in a subject with an abnormal neurological condition is determined and subtypes thereof or tissue types subjected to damage are discerned.

Abstract: The present invention identifies biomarkers that are diagnostic of neural injury, neuronal disorder or neurotoxicity and is related to the discovery that proteases are selectively activated in subjects suffering from nervous system damage as compared to healthy subjects. Breakdown products reflecting protease activation are produced and detection of these different biomarkers of the invention is also diagnostic of the degree of severity and type of nerve damage in a subject.

Abstract: Processes and compositions for the therapeutic treatment of pathogenic Gram-negative bacterial infection are provided whereby argininosuccinate synthetase or PEGylated argininosuccinate synthetase is administered to a subject to inactivate endotoxin thereby reducing the likelihood of bacterial sepsis and improving patient outcome.